RAW SEQUENCE LISTING

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) no errors detected.

Application Serial Number:	09/840,277E
Source:	IFW16
Date Processed by STIC:	1/30/05

ENTERED



IFW16

RAW SEQUENCE LISTING DATE: 01/30/2005 PATENT APPLICATION: US/09/840,277E TIME: 11:55:41

Input Set : A:\A-688A (rev 1-18-05).ST25.txt
Output Set: N:\CRF4\01302005\I840277E.raw

	<110>						ULR	СН									
4		KOHNO, TADAHIKO LACEY, DAVID															
5			•			~···											
6	<1.00×				OMAS			vina.	TON :	N N T (TT) 7N /	2011	200	<i>(</i>		J1\		
	<120>								LON A	ANTA	2ONT;	515	(as a	ameno	iea)		
	<130>								n - 11/	7 AA	/0.40	0771	,				
	<140>										/840,	, 2 / / 1	·				
		> CURRENT FILING DATE: 2001-04-23 > PRIOR APPLICATION NUMBER: US 60/198,919															
		·															
		151> PRIOR FILING DATE: 2000-04-21 150> PRIOR APPLICATION NUMBER: US 60/201,394															
	<151>									00/20	JI, 3:	94			1		
	<160>								5-05								
	<170>								, a ,	2				- (.	<i>)</i> 6		
	<210>					511611	1 667	. 3 . () .	11 9.4	<u> </u>				14			
	<211>		_											M			
	<212>				7 -									4			
	<213>				Homo	sar	oiens	3									
	<220>				110111		71011	•									
	<221>				CDS												
	<222>		-			(68	34)										
	<400>					•	•										
36	atg g	ac	aaa	act	cac	aca	tgt	cca	cct	tgt	сса	gct	ccq	gaa	ctc	ctq	48
	Met A																
38	1				5		_			10					15		-
40	ggg g	ıga	ccg	tca	gtc	ttc	ctc	ttc	ccc	cca	aaa	ccc	aag	gac	acc	ctc	96
41	Gly G	ly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	
42				20					25					30			
44	atg a	tc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	gtg	gtg	gac	gtg	agc	144
	Met I			Arg	Thr	Pro	Glu		Thr	Cys	Val	Val		Asp	Val	Ser	
46			35					40					45				
	cac g																192
	His G		Asp	Pro	Glu	Val		Phe	Asn	Trp	Tyr		Asp	Gly	Val	Glu	
50		0					55					60					
	gtg c																240
	Val H	lis .	Asn	Ala	Lys		Lys	Pro	Arg	Glu		Gln	Tyr	Asn	Ser		
	65					70					75					80	
	tac c																288
	Tyr A	rg	val	val		Val	Leu	Thr	Val		His	GIn	Asp	Trp		Asn	
58					85					90					95		226
	ggc a																336
	Gly L	ys	GIU		ьуѕ	Cys	гÀг	val		Asn	ьys	Ата	ьeu		ΑΙа	Pro	
62				100					105					110			

RAW SEQUENCE LISTING DATE: 01/30/2005 PATENT APPLICATION: US/09/840,277E TIME: 11:55:41

Input Set : A:\A-688A (rev 1-18-05).ST25.txt
Output Set: N:\CRF4\01302005\1840277E.raw

	atc							_			_		-	-		_	384
	Ile	Glu	_	Thr	lle	Ser	гàг		Ьys	GLY	Gin	Pro	_	GLu	Pro	GIn	
66			115					120					125				400
	gtg																432
	Val	_	Thr	Leu	Pro	Pro		Arg	Asp	GLu	Leu		Lys	Asn	GIn	Val	
70		130					135					140					
	agc																480
	Ser	Leu	Thr	Cys	Leu		гуs	GLY	Phe	Tyr		Ser	Asp	Пе	Ala		
	145					150					155					160	
	gag																528
	Glu	Trp	GIU	Ser		GTÀ	GIn	Pro	GIU		Asn	Tyr	гàг	Thr		Pro	
78					165					170					175		576
	CCC																576
	Pro	vaı	ьeu		ser	Asp	GTÀ	Ser		Pne	ьeu	Tyr	Ser	_	ьeu	Thr	
82				180					185					190			
	gtg																624
	Val	Asp	_	Ser	Arg	Trp	GIN		GTA	Asn	vaı	Pne		Cys	Ser	val	
86			195					200					205				67.0
	atg																672
	Met		GIU	Ата	Leu	HIS		His	Tyr	Thr	GIn	_	Ser	Leu	Ser	Leu	
90	44.	210					215					220					604
	tct																684
	Ser 225	Pro	СТУ	ьуѕ													
0.7	~?1A	IN CE	O TE	NIO.	2												
) NO:													
98	<211	> LE	NGTF	H: 22													
98 99	<211 <212	> LE	NGTH	H: 22 PRT	8.8	00 S	nier	c									
98 99 100	<211 <212 <21	> LE > TY .3> C	NGTF PE: RGAN	I: 22 PRT NISM:	8 Hom	no sa	pier	ıs									
98 99 100 102	<211 <212 > <21 > <40	> LE !> TY .3> C	NGTH PE: RGAN EQUE	H: 22 PRT NISM: ENCE:	.8 Hom 2				n Pro	n Cvs	: Pro	n Ala	a Pro	s Glu	ı I.e.	ı I.e.i	
98 99 100 102	<211 <212 ><21 ><21 ? <40 ! Met	> LE !> TY .3> C	NGTH PE: RGAN EQUE	H: 22 PRT NISM: ENCE:	.8 Hom 2) Pro	_	s Pro	o Ala	a Pro	o Glu		ı Leu	
98 99 100 102 104 105	<211 <212 > <21 ? <40 ! Met	> LE > TY .3> C .0> S : Asp	NGTH PE: PRGAN EQUE Lys	PRT PRT NISM: ENCE:	Hom 2 His 5	Thr	Cys	Pro		10					15		
98 99 100 102 104 105 108	<211 <212 <21 <40 Met 5 1 Gly	> LE > TY .3> C .0> S : Asp	NGTH PE: PRGAN EQUE Lys	PRT VISM: ENCE: Thr	Hom 2 His 5	Thr	Cys	Pro	e Pro	10				Asp	15		
98 99 100 102 104 105 108	<211 <212 <21 <40 Met 5 1 8 Gly	> LE > TY .3> C .0> S . Asp	NGTH PE: PRGAN EQUE Lys	PRT NISM: ENCE: Thr Ser 20	Hom 2 His 5 Val	Thr Phe	Cys	Pro	Pro 25	10 Pro	Lys	s Pro	Lys	Asp 30	15 Thi	Leu	
98 99 100 102 104 105 108	<211 <212) <212) <40 ! Met i 1 B Gly) Met	> LE > TY .3> C .0> S . Asp	NGTH PE: PRGAN EQUE Lys	PRT NISM: ENCE: Thr Ser 20	Hom 2 His 5 Val	Thr Phe	Cys	Pro	Pro 25	10 Pro	Lys	s Pro	Lys	Asp 30	15 Thi		
98 99 100 102 104 105 108 112 113	<211 <212) <21 2 <40 ! Met 5 1 8 Gly 9	> LE > TY .3> C 00> S : Asp ' Gly	ENGTH PE: PRGAN EEQUE Lys Pro	PRT VISM: CNCE: Thr Ser 20 Arg	Hom 2 His 5 Val	Thr Phe	Cys Leu Glu	Pro Phe Val 40	Pro 25 Thi	10 Pro	Lys Val	Pro Val	Lys Val	30 Asp	15 Thi	Leu Ser	
98 99 100 102 104 105 108 112 113	<211 <212) <212 2 <40 Met 5 1 3 Gly 2 Met 5 His	> LE > TY 3> C 0> S Asp Gly	ENGTH PE: PRGAN EEQUE Lys Pro	PRT VISM: CNCE: Thr Ser 20 Arg	Hom 2 His 5 Val	Thr Phe	Cys Leu Glu	Pro Phe Val 40	Pro 25 Thi	10 Pro	Lys Val	Pro Val	Lys Val	30 Asp	15 Thi	Leu	
98 99 100 102 104 105 108 112 113 116	<211 <212) <212 2 <40 Met 5 1 8 Gly Het 8 His	> LE > TY 3> C 0> S Asp Gly : Ile : Glu	PE: PRGAN EQUE Pro Pro Ser 35 Asp	PRT PRT VISM: ENCE: Thr 20 Ser 20 Arg	Hom 2 His 5 Val Thr	Thr Phe Pro	Cys Lev Glu Lys 55	Pro Phe Val 40 Phe	Pro 25 Thi	10 Pro Cys	Lys Val	Val	Val 45 Asp	30 Asp Asp	15 Thi Val	Leu Ser Glu	
98 99 100 102 104 105 108 112 113 116	<211 <212 <212 <216 <217 <218 <218 <219 <219 <219 <219 <219 <219 <219 <219	> LE > TY 3> C 0> S Asp Gly : Ile : Glu	PE: PRGAN EQUE Pro Pro Ser 35 Asp	PRT PRT VISM: ENCE: Thr 20 Ser 20 Arg	Hom 2 His 5 Val Thr	Thr Phe Pro Val	Cys Lev Glu Lys 55	Pro Phe Val 40 Phe	Pro 25 Thi	10 Pro Cys	Lys Val Tyr	Val	Val 45 Asp	30 Asp Asp	15 Thi Val	Leu Ser Glu	
98 99 100 102 104 105 108 112 113 116 120 121	<211 <212 <212 <400 Met 5 1 B Gly B His Val 65	> LE > TY .3> C 00> S Asp / Gly . Ile . Glu . His	NGTH PE: PRGAN EQUE Pro Ser 35 Asp	PRT JISM: JISM: ENCE: Thr Ser 20 Arg	Hom 2 His 5 Val Thr Glu	Thr Phe Pro Val Thr 70	Cys Leu Glu Lys 55 Lys	Phe Val 40 Phe	Pro 25 Thi Asr	10 Pro Cys Trp Glu	Lys Val Tyr Glu 75	Val Val 60 Glr	Val 45 Asp	Asp 30 Asp Gly	15 Thi Val Val	L Ser Glu Thr	
98 99 100 102 104 105 112 113 116 117 120 121	<211 <212 <212 <40 <40 <40 <40 <40 <40 <40 <40 <40 <40	> LE > TY .3> C 00> S Asp / Gly . Ile . Glu . His	NGTH PE: PRGAN EQUE Pro Ser 35 Asp	PRT JISM: JISM: ENCE: Thr Ser 20 Arg	Hom 2 His 5 Val Thr Glu	Thr Phe Pro Val Thr 70	Cys Leu Glu Lys 55 Lys	Phe Val 40 Phe	Pro 25 Thi Asr	10 Pro Cys Trp Glu	Lys Val Tyr Glu 75	Val Val 60 Glr	Val 45 Asp	Asp 30 Asp Gly	15 Thi Val Val	Leu Ser Glu	
98 99 100 102 104 105 108 112 113 116 120 121 124 125	<211 <212) <21) <21) <40) Met 5 1 8 Gly 9 2 Met 8 His 5 His 7 Val 65 Tyr 6	> LE > TY .3> C 00> S . Asp . Gly . Ile . 50 . His	NGTH PE: PRGAN EQUE Pro Ser 35 Asp Asr	PRT PRT VISM: ENCE: Thr 20 Ser Argo Pro	Hom 2 His 5 Val Thr Glu Lys	Thr Phe Pro Val Thr 70	Cys Leu Glu Lys 55 Lys	Pho Pho Val 40 Pho Pro	Pro 25 Thi Asr	10 Pro Pro Cys Trp Glu Leu 90	Val Val Tyr Glu 75	Val Val 60 Glr	Val 45 Asp Tyr	Asp 30 Asp Gly Asn	15 Thi Val Val Sei Lei 95	Leu Ser Glu Thr 80 Asn	
98 99 100 102 104 105 108 112 113 116 120 121 124 125	<211 <212 <212 <40 40 40 40 40 40 40 40 40 40 40 40 40 4	> LE > TY .3> C 00> S . Asp . Gly . Ile . 50 . His	NGTH PE: PRGAN EQUE Pro Ser 35 Asp Asr	PRT PRT VISM: ENCE: Thr 20 Ser Argo Pro	Hom 2 His 5 Val Thr Glu Lys Ser 85	Thr Phe Pro Val Thr 70	Cys Leu Glu Lys 55 Lys	Pho Pho Val 40 Pho Pro	Pro 25 Thi Asr	10 Pro Cys Trp Glu Leu 90 Asr	Val Val Tyr Glu 75	Val Val 60 Glr	Val 45 Asp Tyr	Asp 30 Asp Gly Asn	15 Thi Val Val Sei Lei 95 Ala	L Ser Glu Thr	
98 99 100 102 104 105 108 112 113 116 117 120 121 124 125 128	<211 <212 <212 <40 40 40 40 40 40 40 40 40 40 40 40 40 4	> LE > TY 3> CO 00> S Asp Gly 50 His	NGTH PE: PRGAN EQUE Lys Pro Ser 35 Asp Asr Val	PRT PRT VISM: ENCE: Thr 20 Ser Argo Pro Ala Val	Hom 2 His 5 Val Thr Glu Lys Ser 85 Lys	Phe Pro Val	Cys Leu Glu Lys 55 Lys Leu Lys	Property Phenomena Phenome	Pro 25 Thi Asr Arg Val	10 Pro	Val Val Tyr 75 His	Val Val 60 Glr Glr	Val 45 Asp Tyr Asp	Asp 30 Asp Gly Asr Trp	15 Thi Val Val Sei 1 Sei 95 Ala	Leu Ser Glu Thr 80 1 Asn	
98 99 100 102 104 105 108 112 113 116 117 120 121 124 125 128	<211 <212 <212 <216 <2 40 <3 61 <5 1 <5 His <5 His <5 Gly	> LE > TY 3> CO 00> S Asp Gly 50 His	NGTH PE: PRGAN EQUE Lys Pro Ser 35 Asp Asr Val	PRT VISM: ENCE: Thr 20 Ser Argo Pro Ala Val	Hom 2 His 5 Val Thr Glu Lys Ser 85 Lys	Phe Pro Val	Cys Leu Glu Lys 55 Lys Leu Lys	Property Phenomena Phenome	Pro 25 Third Asr Arc Val. Ser 105 Lys	10 Pro	Val Val Tyr 75 His	Val Val 60 Glr Glr	Val 45 Asp Tyr Asp	Asp 30 Asp Gly Asr Trp Pro 110	15 Thi Val Val Sei 1 Sei 95 Ala	Leu Ser Glu Thr 80 Asn	
98 99 100 102 104 105 108 109 112 113 116 121 122 128 129 132 133	<211 <212 <212 <216 <2 40 <3 Gly <4 Met <5 1 <6 Met <5 1 <4 Met <5 1 <6 Met <5	> LE > TY 3> C 10> S Asp Gly 50 His Arg	NGTH PE: PRGAN EQUE Lys Pro Ser 35 Asr Val Uys 115	PRT VISM: ENCE: Thr 20 Pro Ala Val	Hom 2 His 5 Val Thr Clu Lys Ser 85 Lys Ile	Thr. Phe Pro Val. Thr. 70 Val. Cys. Ser.	Cys Leu Glu Lys 55 Lys Leu Lys	Property Phenomena Phenome	25 Thie Asr Arc Val	10 Pro Cys Trp Glu Leu 90 Asn	Value	Val Val 60 Glr Glr Ala	Val 45 Asp Tyr Asp Leu Arg	Asp 30 Asp Gly Asr Pro 110	15 Thi Val Val Sei Sei Pro	Leu Ser Glu Thr 80 Asn Pro	
98 99 100 102 104 105 108 109 112 113 116 121 122 128 129 132 133	<211 <212 <212 <216 <217 <218 <218 <219 <219 <219 <219 <219 <219 <219 <219	> LE > TY 3> C 10> S Asp Gly 50 His Arg	NGTH PE: PRGAN EQUE Lys Pro Ser 35 Asr Val Uys 115	PRT VISM: ENCE: Thr 20 Pro Ala Val	Hom 2 His 5 Val Thr Clu Lys Ser 85 Lys Ile	Thr. Phe Pro Val. Thr. 70 Val. Cys. Ser.	Cys Leu Glu Lys 55 Lys Leu Lys	Phe Val 40 Phe Pro Thr Val Ala 120	25 Thie Asr Arc Val	10 Pro Cys Trp Glu Leu 90 Asn	Value	Val Val 60 Glr Glr Ala	Value	Asp 30 Asp Gly Asr Pro 110	15 Thi Val Val Sei Sei Pro	Leu Ser Glu Thr 80 1 Asn	
98 99 100 102 104 105 108 112 113 116 117 120 121 128 133 136 137	<211 <212 <212 <216 <217 <218 <218 <218 <219 <219 <219 <219 <219 <219 <219 <219	> LE > TY 3> C 00> S Asp Gly Ile 50 His Arg Lys Glu	NGTH PE: PRGAN EQUE Lys Pro Ser 35 Asr Val Glu Lys 115	PRT VISM: ENCE: Thr 20 Pro Ala Val 100 Thr 100	Hom 2 His 5 Val Thr Glu Lys Lys Lys	Thr. Phe Pro Val Thr 70 Val Cys Ser	Cys Lev Clu Lys Lys Lys Lys Lys Ser 135	Phe Val 40 Phe Pro Thr Val Ala 120	25 Thie Asr Arc Val Ser 105 Lys	10 Pro Cys Trp Glu Leu 90 Asn	Val Val Tyr 75 His Lys Glr	Val Val 60 Glr Glr Ala Pro	Value	Asp 30 Asp Gly Asr Pro 110 Glu	15 Thi Val Val Sei 95 Ala Pro	Leu Ser Glu Thr 80 Asn Pro Gln Val	
98 99 100 102 104 105 108 112 113 116 121 124 125 133 136 137 140	<211 <212 <212 <216 <217 <218 <218 <218 <219 <219 <219 <219 <219 <219 <219 <219	> LE > TY 3> C 10> S Asp Gly : Ile 50 : His Arg Lys : Glu : Tyr 130	NGTH PE: PRGAN EQUE Lys Pro Ser 35 Asr Val Glu Lys 115	PRT VISM: ENCE: Thr 20 Pro Ala Val 100 Thr 100	Hom 2 His 5 Val Thr Glu Lys Lys Lys	Thr. Phe Pro Val Thr 70 Val Cys Ser	Cys Lev Glu Lys 55 Lys Lys Lys Ser 135 Lys	Phe Val 40 Phe Pro Thr Val Ala 120	25 Thie Asr Arc Val Ser 105 Lys	10 Pro Cys Trp Glu Leu 90 Asn	Val Val Tyr 75 His Lys Glr	Val Val 60 Glr Glr Ala Pro 140 Ser	Value	Asp 30 Asp Gly Asr Pro 110 Glu	15 Thi Val Val Sei 95 Ala Pro	Leu Ser Glu Thr 80 Asn Pro	

RAW SEQUENCE LISTING DATE: 01/30/2005 PATENT APPLICATION: US/09/840,277E TIME: 11:55:41

Input Set : A:\A-688A (rev 1-18-05).ST25.txt
Output Set: N:\CRF4\01302005\I840277E.raw

```
144 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
                    165
                                         170
148 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
149
                180
                                    185
                                                         190
152 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
            195
                                200
                                                     205
156 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
        210
                            215
160 Ser Pro Gly Lys
161 225
164 <210> SEQ ID NO: 3
165 <211> LENGTH: 8
166 <212> TYPE: PRT
167 <213> ORGANISM: Artificial Sequence
169 <220> FEATURE:
170 <223> OTHER INFORMATION: Preferred linker
172 <400> SEQUENCE: 3
174 Gly Gly Gly Lys Gly Gly Gly
175 1
178 <210> SEQ ID NO: 4
179 <211> LENGTH: 8
180 <212> TYPE: PRT
181 <213> ORGANISM: Artificial Sequence
183 <220> FEATURE:
184 <223> OTHER INFORMATION: Preferred linker
186 <400> SEQUENCE: 4
188 Gly Gly Gly Asn Gly Ser Gly Gly
189 1
192 <210> SEQ ID NO: 5
193 <211> LENGTH: 8
194 <212> TYPE: PRT
195 <213> ORGANISM: Artificial Sequence
197 <220> FEATURE:
198 <223> OTHER INFORMATION: Preferred linker
200 <400> SEQUENCE: 5
202 Gly Gly Gly Cys Gly Gly Gly
203 1
206 <210> SEQ ID NO: 6
207 <211> LENGTH: 5
208 <212> TYPE: PRT
209 <213> ORGANISM: Artificial Sequence
211 <220> FEATURE:
212 <223> OTHER INFORMATION: Preferred linker
214 <400> SEQUENCE: 6
216 Gly Pro Asn Gly Gly
217 1
220 <210> SEQ ID NO: 7
221 <211> LENGTH: 5
222 <212> TYPE: PRT
```

RAW SEQUENCE LISTING DATE: 01/30/2005 PATENT APPLICATION: US/09/840,277E TIME: 11:55:41

Input Set: A:\A-688A (rev 1-18-05).ST25.txt
Output Set: N:\CRF4\01302005\I840277E.raw

```
223 <213> ORGANISM: Artificial Sequence
     225 <220> FEATURE:
     226 <223> OTHER INFORMATION: Laminin peptide
     228 <400> SEQUENCE: 7
     230 Tyr Ile Gly Ser Arg
     231 1
     234 <210> SEQ ID NO: 8
     235 <211> LENGTH: 49
     236 <212> TYPE: PRT
     237 <213> ORGANISM: Artificial Sequence
     239 <220> FEATURE:
     240 <223> OTHER INFORMATION: Echistatin peptide
     242 <400> SEQUENCE: 8
     244 Glu Cys Glu Ser Gly Pro Cys Cys Arg Asn Cys Lys Phe Leu Lys Glu
     248 Gly Thr Ile Cys Lys Arg Ala Arg Gly Asp Asp Met Asp Asp Tyr Cys
                     20
                                          25
     252 Asn Gly Lys Thr Cys Asp Cys Pro Arg Asn Pro His Lys Gly Pro Ala
     253
     256 Thr
     260 <210> SEQ ID NO: 9
     261 <211> LENGTH: 7
     262 <212> TYPE: PRT
     263 <213> ORGANISM: Artificial Sequence
     265 <220> FEATURE:
     266 <223> OTHER INFORMATION: RGD, NGR derivative peptide
     269 <220> FEATURE:
     270 <221> NAME/KEY: misc_feature
     271 <222> LOCATION: (2, \overline{5} \text{ and})...(7)
     272 <223> OTHER INFORMATION: Xaa is any amino acid
     274 <400> SEQUENCE: 9
W--> 276 Arg Xaa Glu Thr Xaa Trp Xaa
     277 1
     280 <210> SEQ ID NO: 10
     282 <400> SEQUENCE: 10
W--> 283 000
     285 <210> SEQ ID NO: 11
     286 <211> LENGTH: 9
     287 <212> TYPE: PRT
     288 <213> ORGANISM: Artificial Sequence
     290 <220> FEATURE:
     291 <223> OTHER INFORMATION: RGD, NGR derivative peptide
     294 <220> FEATURE:
     295 <221> NAME/KEY: misc feature
     296 <222> LOCATION: (2, 3, 7 and)..(8)
     297 <223> OTHER INFORMATION: Xaa is any amino acid
     299 <400> SEQUENCE: 11
W--> 301 Cys Xaa Xaa Arg Leu Asp Xaa Xaa Cys
     302 1
```

DATE: 01/30/2005

TIME: 11:55:41

```
Input Set : A:\A-688A (rev 1-18-05).ST25.txt
                     Output Set: N:\CRF4\01302005\I840277E.raw
     305 <210> SEQ ID NO: 12
     307 <400> SEQUENCE: 12
W--> 308 000
     310 <210> SEQ ID NO: 13
     311 <211> LENGTH: 9
     312 <212> TYPE: PRT
     313 <213> ORGANISM: Artificial Sequence
     315 <220> FEATURE:
     316 <223> OTHER INFORMATION: RGD, NGR derivative peptide
     319 <220> FEATURE:
     320 <221> NAME/KEY: misc feature
     321 <222> LOCATION: (1, \overline{2}, 3, 7, 8 \text{ and})..(9)
     322 <223> OTHER INFORMATION: Xaa is any amino acid with Xaa at 1, 3, 7 and 9 capable of
     323
               forming a bridge.
     325 <400> SEQUENCE: 13
W--> 327 Xaa Xaa Xaa Arg Gly Asp Xaa Xaa Xaa
     328 1
     331 <210> SEQ ID NO: 14
     332 <211> LENGTH: 17
     333 <212> TYPE: PRT
     334 <213> ORGANISM: Artificial Sequence
     336 <220> FEATURE:
     337 <223> OTHER INFORMATION: RGD, NGR derivative peptide
     340 <220> FEATURE:
     341 <221> NAME/KEY: misc feature
     342 <222> LOCATION: (2, 3, 4, 5, 6, 12, 13, 14, 15 and)..(16)
     343 <223> OTHER INFORMATION: At positions 2, 3, 4, 5, 6, 12, 13, 14, 15 and 16, Xaa is
any
               amino acid or may be absent.
     344
     346 <400> SEQUENCE: 14
W--> 348 Cys Xaa Xaa Xaa Xaa Cys Arg Gly Asp Cys Xaa Xaa Xaa Xaa Xaa
     349 1
                         5
                                              10
     352 Cys
     356 <210> SEQ ID NO: 15
     357 <211> LENGTH: 8
     358 <212> TYPE: PRT
     359 <213> ORGANISM: Artificial Sequence
     361 <220> FEATURE:
     362 <223> OTHER INFORMATION: RGD, NGR derivative peptide
     365 <220> FEATURE:
     366 <221> NAME/KEY: misc_feature
     367 <222> LOCATION: (1 and)..(8)
     368 <223> OTHER INFORMATION: Xaa is an independently selected amino acid.
     370 <220> FEATURE:
     371 <221> NAME/KEY: misc feature
     372 <222> LOCATION: (2 and)..(7)
     373 <223> OTHER INFORMATION: Xaa is any amino acid, each which is independently selected.
     375 <220> FEATURE:
     376 <221> NAME/KEY: misc feature
     377 <222> LOCATION: (5)..(5)
```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/840,277E

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 01/30/2005 PATENT APPLICATION: US/09/840,277E TIME: 11:55:42

Input Set: A:\A-688A (rev 1-18-05).ST25.txt
Output Set: N:\CRF4\01302005\I840277E.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

```
Seq#:9; Xaa Pos. 2,5,7
Seg#:11; Xaa Pos. 2,3,7,8
Seq#:13; Xaa Pos. 1,2,3,7,8,9
Seq#:14; Xaa Pos. 2,3,4,5,6;12,13,14,15,16
Seq#:15; Xaa Pos. 1,2,5,6,7,8
Seq#:16; Xaa Pos. 1,2,3,6,7,8,9,10
Seq#:17; Xaa Pos. 3,5,6,13,15
Seq#:18; Xaa Pos. 2,3,4,7,15
Seg#:19; Xaa Pos. 3,4,5,6,8,13,15,18
Seq#:20; Xaa Pos. 2,5,6,7,12,13,14
Seq#:21; Xaa Pos. 1,3,6,9,12,13
Seq#:40; Xaa Pos. 3,4
Seq#:50; Xaa Pos. 2,3
Seq#:58; Xaa Pos. 5
Seq#:59; Xaa Pos. 6
Seq#:86; Xaa Pos. 3,15
Seq#:87; Xaa Pos. 13,15
Seq#:138; Xaa Pos. 1,4,5,6
Seq#:139; Xaa Pos. 1,2,5,6,7
Seq#:140; Xaa Pos. 1,2,3,6,7,8
Seq#:141; Xaa Pos. 1,2,3,4,5,8,9,10
Seq#:142; Xaa Pos. 1,4,5,6,7
Seq#:143; Xaa Pos. 1,2,3,6,7,8
Seq#:144; Xaa Pos. 1,2,3,6,7,8,9
Seq#:145; Xaa Pos. 1,2,3,4,7,8,9,10
Seq#:146; Xaa Pos. 1,2,3,4,5,8,9,10,11
Seq#:147; Xaa Pos. 1,4,5,6,7,8
Seq#:148; Xaa Pos. 1,2,5,6,7,8,9
Seq#:149; Xaa Pos. 1,2,3,6,7,8,9,10
Seq#:150; Xaa Pos. 1,2,3,4,7,8,9,10,11
Seq#:151; Xaa Pos. 1,2,3,4,5,8,9,10,11,12
Seq#:152; Xaa Pos. 1,4,5,6,7,8,9
Seg#:153; Xaa Pos. 1,2,5,6,7,8,9,10
Seq#:154; Xaa Pos. 1,2,3,6,7,8,9,10,11
Seq#:155; Xaa Pos. 1,2,3,4,7,8,9,10,11,12
Seq#:156; Xaa Pos. 1,2,3,4,5,8,9,10,11,12,13
Seq#:157; Xaa Pos. 1,4,5,6,7,8,9,10
Seq#:158; Xaa Pos. 1,2,5,6,7,8,9,10,11
Seq#:159; Xaa Pos. 1,2,3,6,7,8,9,10,11,12
Seq#:160; Xaa Pos. 1,2,3,4,7,8,9,10,11,12,13
Seq#:161; Xaa Pos. 1,2,3,4,5,8,9,10,11,12,13,14
```

VERIFICATION SUMMARY PATENT APPLICATION: US/09/840,277E DATE: 01/30/2005 TIME: 11:55:42

Input Set: A:\A-688A (rev 1-18-05).ST25.txt
Output Set: N:\CRF4\01302005\I840277E.raw

```
L:276 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:0
L:283 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (10) SEQUENCE:
L:301 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11 after pos.:0
L:308 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (12) SEQUENCE:
L:327 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13 after pos.:0
L:348 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14 after pos.:0
L:388 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15 after pos.:0
L:436 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16 after pos.:0
L:456 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17 after pos.:0
L:480 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18 after pos.:0
L:500 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19 after pos.:0
M:341 Repeated in SegNo=19
L:524 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20 after pos.:0
L:544 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21 after pos.:0
L:816 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:40 after pos.:0
L:962 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50 after pos.:0
L:1108 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:58 after pos.:0
L:1128 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:59 after pos.:0
L:1524 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:86 after pos.:0
L:1544 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:87 after pos.:0
L:2634 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:138 after pos.:0
L:2670 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:139 after pos.:0
L:2706 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:140 after pos.:0
L:2742 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:141 after pos.:0
L:2778 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:142 after pos.:0
L:2814 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:143 after pos.:0
L:2850 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:144 after pos.:0
L:2886 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:145 after pos.:0
L:2922 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:146 after pos.:0
L:2958 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:147 after pos.:0
L:2994 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:148 after pos.:0
L:3030 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:149 after pos.:0
L:3066 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:150 after pos.:0
L:3102 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:151 after pos.:0
L:3138 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:152 after pos.:0
L:3174 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:153 after pos.:0
L:3210 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:154 after pos.:0
L:3246 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:155 after pos.:0
L:3282 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:156 after pos.:0
L:3318 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:157 after pos.:0
L:3354 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:158 after pos.:0
L:3390 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:159 after pos.:0
L:3426 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:160 after pos.:0
L:3462 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:161 after pos.:0
```